We also conducted similar experiments using the PARP1‐specific inhibitor AZD5305 and found that while AZD5305 alone had no significant effect, combining it with HMGA1 knockdown significantly inhibited tumour size, volume, and weight (Figure S6B–D). The gene discussed is PARP1; the disease is neoplasm.